What is MacroGenics?
MacroGenics, Inc. is a publicly traded biotechnology enterprise focused on the discovery, development, and commercialization of antibody-based therapeutics. The company operates at the intersection of immuno-oncology and advanced biologics manufacturing, utilizing proprietary engineering platforms to enhance the immune system's capacity to target and eliminate cancer cells. By integrating translational medicine with rigorous clinical development, MacroGenics addresses complex oncology indications, positioning itself as a high-authority entity in the life sciences market. The company's business model relies on a combination of internal research and strategic partnerships to bring novel medicines to patients globally.
How much funding has MacroGenics raised?
MacroGenics has raised a total of $559M across 10 funding rounds:
Series D
$25M
Grant
$9.8M
Stock Offering
$83.8M
Stock Offering
$76.7M
Stock Offering
$141M
Stock Offering
$23.6M
Stock Offering
$110M
Series D (2008): $25M featuring Alexandria, Alta Partners, OrbiMed, Arcus Ventures, TPG Ventures, CIDC, Ventures West, InterWest Partners, Mitsubishi UFJ, Nextech Venture, Eli Lilly and Company, RiverVest, Innovis Investments, and Red Abbey Venture Partners
Grant (2010): $9.8M backed by National Institutes of Health
Stock Issuance/Offering (2013): $83.8M with participation from Undisclosed
Stock Issuance/Offering (2014): $76.7M led by Undisclosed
Stock Issuance/Offering (2015): $141M supported by Undisclosed
Stock Issuance/Offering (2017): $23.7M featuring Undisclosed
Stock Issuance/Offering (2018): $110M backed by Undisclosed
Key Investors in MacroGenics
OrbiMed
OrbiMed Advisors LLC is a specialized investment firm focused on the healthcare sector, managing capital across biopharmaceuticals, medical devices, and digital health platforms to support innovation at various development stages.
MPM Capital
MPM BioImpact manages early-stage venture funds and private/public impact funds, dedicated to converting scientific research into life-saving therapeutics.
Alta Partners
Alta Partners is a prominent venture capital firm specializing in healthcare and life sciences, focused on supporting entrepreneurs who build impactful companies that enhance patient outcomes.
What's next for MacroGenics?
Looking ahead, MacroGenics is well-positioned to capitalize on its established research infrastructure and the momentum provided by its recent strategic investment. The company's focus remains on advancing its pipeline of immuno-oncology candidates through late-stage clinical trials and potential commercialization. As the biotechnology industry faces evolving regulatory and competitive pressures, MacroGenics' ability to sustain its innovation cycle will be critical. The organization is expected to prioritize operational efficiency and the expansion of its therapeutic portfolio, ensuring that its proprietary antibody technologies continue to provide meaningful clinical benefits to patients while delivering long-term value to stakeholders.
See full MacroGenics company page
